Michael Cilento

Proud to co-author this Review with Prof @ChrisSweens1, whose leadership and dedication continue to advance care for people affected by prostate cancer. Published in @NatRevClinOncol. #prostatecancer #pcsm @LisaButler5 @drlouiseemmett

Personalized intensification of treatment for hormone-sensitive prostate cancer nature.com/articles/s4157… Hormone-sensitive #ProstateCancer (HSPC) management has advanced beyond androgen-deprivation therapy (ADT) alone, now incorporating androgen receptor pathway inhibitors (ARPIs), docetaxel, and radiotherapy based on disease state and biology. Modern PSMA PET imaging detects metastases earlier than conventional scans, redefining patient subgroups and influencing decisions such as when to use chemotherapy or radiotherapy. Treatment is increasingly personalized, guided by prior local therapy, PSA dynamics, disease volume, and imaging findings, with ARPI–ADT doublets forming the backbone for metastatic disease. Attention to toxicity from long-term testosterone suppression is crucial, while emerging biomarker-driven therapies—including ^177Lu-PSMA-617, AKT inhibitors, and PARP inhibitors—are poised to further refine care. @drcilento @LisaButler5 @drlouiseemmett @ChrisSweens1 @OncoAlert 🚨 @Silke_Gillessen @AOmlin @weoncologists

Thanks for sharing @OscarTahuahua!

The second #ProstateCancer session at #UromigosLive 2025 was a discussion about the approach to mHSPC, building on ADT+ARPI and debating the inclusion of a third agent including docetaxel, PARPi, radioligand or AKT inhibition. Uromigos.org for full videos with slides. @OncoAlert

1/ 🚨 Pleased to share that our latest manuscript is out now in @EUplatinum! Baseline and on-treatment #ctDNA biomarkers in men with advanced #ProstateCancer treated with #LuPSMA. bit.ly/4nzJRyV Thanks to @LouiseKostos Heidi Fettke @PeterMacCC

Immune checkpoint inhibitors can improve survival in solid organ transplant recipients with advanced cancers, but survival rates remain limited. #TSANZConf @TSANZ_txsoc ja.ma/43Rsa7C

📢#ASCO25 concomitant publication: BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic HSPC: prevalence and impact on outcomes @Dolmos77 @Dav_Lorente @igginel @nromerolaorden @casilda_llacer @cdanicas @BerUrologia tinyurl.com/yyd25nbc

Stunning research from @EdmondMKwan on ctDNA in theranostics: 🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy ⚠️PTEN alterations linked to worse outcomes on cabazitaxel 🧪ATM defects tied to favorable PSMA-617 results 🩻PET quantitative biomarkers (SUVmean) are additive 🌟We identify new candidate biomarkers for ¹⁷⁷Lu–PSMA-617 selection and ultimately expand the mCRPC predictive biomarker repertoire Online at @NatureMedicine nature.com/articles/s4159… @ANZUPtrials #TheraP @MovemberAUS @PCFA Support by @PCF_Science Challenge Award @ResearchWyatt @AzadOncology @Prof_IanD

Time to Treatment Initiation for the 30 Most Prevalent #Cancer Types: Trends and Predictors of Change. ascopubs.org/doi/10.1200/OP… @ASCO @JCO_ASCO @JCOOP_ASCO #CancerTreatment #CancerResearch #CancerCare

Great to see a full-house for @SAiGENCI's third Annual Public Lecture on Tuesday night featuring @Lab_Jenkins and @marazeissig speaking on the topic of "Fighting cancer from within: your immune system may hold the key" youtube.com/watch?v=z2KcRI… @UniofAdelaide

Congrats @ANZUPtrials #ENZAp study positive OS & QoL results presented by @drlouiseemmett @ASCSO #GU25 & published @TheLancet. @MovemberAUS @CancerAustralia @AstellasEurope #ARTnet @StVincentClinic @RoyMorganAus @Novartis @mimsoftware @GenesisCare @ANSTO @TrialsCentre @Prof_IanD

Recently published: #ClonalHematopoiesis of Indeterminate Potential (CHIP) & Its Association with Treatment Outcomes & Adverse Events in Patients with Solid Tumours. doi.org/10.1158/2767-9… @jonathanloree @jaypsv @rob_vanner @PancreasBC @BCCancer #openaccess

Latest journey in #prostatecancer cell plasticity. Team effort @ChrisSweens1 @kat_morel @BeatrizGerFalc Work stems from previous @ChrisSweens1 investigations in NFkB regulation by tristetraprolin (TTP; gene ZFP36), and generation of the NFkBi dimethylaminoparthenolide (DMAPT)

Announcing further @SAiGENCI grant success with @LanKhuyenNguyen, @marazeissig and @drcilento awarded funding from @tourdecure_aus to further their work in prostate and pancreatic cancers. Read more at adelaide.edu.au/newsroom/news/… @UniofAdelaide 👏👊🎉

Congratulating @SAiGENCI legends @LisaButler5 and @Mohamed_I_Saad on their NHMRC Ideas Grant success! See project details at adelaide.edu.au/newsroom/news/… @UniofAdelaide 👏👊🎉

Thrilled to receive this generous support from @SA_genomics & @BioplatformsAus for our project! Looking forward to taking the next steps with an amazing team including @LGMartelotto @LisaButler5 @ChrisSweens1 ,Marten Snel & Kristen Feher! ⭐️🧬🔬

🌟Support SAiGENCI Cancer Research and help fund groundbreaking science! Plus, you can double your impact through matched giving on Giving Day! Let's make a lasting impact together. 💪🌍 #UoAGivingDay #UAMakeHistory Donate now! adelaideuni.co/GivingDay-SAiG…

Nice work Team SAiGENCI raising over $1,300 for cancer research at today's @TheLongestTable morning tea. Not too late to donate at thelongesttable.com.au/fundraisers/sa… Together let's #forkcancer! @hosp_research @UniofAdelaide 👊

@LisaButler5 @SAiGENCI @ChrisSweens1 Couldn’t agree more. A great #ANZUP24 meeting with great people!

Always great to catch up with colleagues and friends at #ANZUP24 our biggest meeting so far! @drcilento and I flying the flag for @SAiGENCI while @ChrisSweens1 was still on the dance floor 😂🪩